Patricia García-Lloret , Mercedes Galván-Banqueri , María de las Aguas Robustillo-Cortés , María Fernández-Recio
{"title":"单克隆抗体再治疗慢性/阵发性偏头痛的分析：真实世界的数据。","authors":"Patricia García-Lloret , Mercedes Galván-Banqueri , María de las Aguas Robustillo-Cortés , María Fernández-Recio","doi":"10.1016/j.farma.2024.02.003","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>To analyze the response to retreatment in patients with chronic/episodic migraine who discontinued therapy with erenumab/fremanezumab after 1 year of treatment.</p></div><div><h3>Methods</h3><p>Observational, retrospective, single-center, multidisciplinary study in patients with chronic/episodic migraine who received therapy with erenumab/fremanezumab for at least 1 year and discontinued it after achieving an adequate response (optimization). The evaluation of the response after retreatment included the following variables: DMM, MIDAS, and HIT-6 scales at the beginning of retreatment and 3 months later. The response was evaluated in different subgroups (episodic/chronic, erenumab/fremanezumab, and time until retreatment).</p></div><div><h3>Results</h3><p>48 patients were included. 70.8% (<em>n</em> <!-->=<!--> <!-->34) required retreatment with mAb, with a median of 3.9 (2.9–6.4) months until reintroduction. Clinical response after retreatment was achieved in 67.6% (<em>n</em> <!-->=<!--> <!-->23) of patients. No statistically significant differences were found in the analyzed subgroups.</p></div><div><h3>Conclusion</h3><p>Interruption of treatment with erenumab/fremanezumab for chronic/episodic migraine produces a clinical worsening of the disease requiring retreatment in most cases, approximately after 4 months. Two out of three patients respond positively after restarting monoclonal therapy. This response does not appear to be related to the type of migraine, the specific monoclonal antibody prescribed, or the time to retreatment.</p></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":null,"pages":null},"PeriodicalIF":1.0000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1130634324000230/pdfft?md5=02b70001951d147fbddf2188c93d7139&pid=1-s2.0-S1130634324000230-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Analysis of retreatment with monoclonal antibodies in chronic/episodic migraine: Real world data\",\"authors\":\"Patricia García-Lloret , Mercedes Galván-Banqueri , María de las Aguas Robustillo-Cortés , María Fernández-Recio\",\"doi\":\"10.1016/j.farma.2024.02.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><p>To analyze the response to retreatment in patients with chronic/episodic migraine who discontinued therapy with erenumab/fremanezumab after 1 year of treatment.</p></div><div><h3>Methods</h3><p>Observational, retrospective, single-center, multidisciplinary study in patients with chronic/episodic migraine who received therapy with erenumab/fremanezumab for at least 1 year and discontinued it after achieving an adequate response (optimization). The evaluation of the response after retreatment included the following variables: DMM, MIDAS, and HIT-6 scales at the beginning of retreatment and 3 months later. The response was evaluated in different subgroups (episodic/chronic, erenumab/fremanezumab, and time until retreatment).</p></div><div><h3>Results</h3><p>48 patients were included. 70.8% (<em>n</em> <!-->=<!--> <!-->34) required retreatment with mAb, with a median of 3.9 (2.9–6.4) months until reintroduction. Clinical response after retreatment was achieved in 67.6% (<em>n</em> <!-->=<!--> <!-->23) of patients. No statistically significant differences were found in the analyzed subgroups.</p></div><div><h3>Conclusion</h3><p>Interruption of treatment with erenumab/fremanezumab for chronic/episodic migraine produces a clinical worsening of the disease requiring retreatment in most cases, approximately after 4 months. Two out of three patients respond positively after restarting monoclonal therapy. This response does not appear to be related to the type of migraine, the specific monoclonal antibody prescribed, or the time to retreatment.</p></div>\",\"PeriodicalId\":45860,\"journal\":{\"name\":\"FARMACIA HOSPITALARIA\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2024-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S1130634324000230/pdfft?md5=02b70001951d147fbddf2188c93d7139&pid=1-s2.0-S1130634324000230-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"FARMACIA HOSPITALARIA\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1130634324000230\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"FARMACIA HOSPITALARIA","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1130634324000230","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Analysis of retreatment with monoclonal antibodies in chronic/episodic migraine: Real world data
Objective
To analyze the response to retreatment in patients with chronic/episodic migraine who discontinued therapy with erenumab/fremanezumab after 1 year of treatment.
Methods
Observational, retrospective, single-center, multidisciplinary study in patients with chronic/episodic migraine who received therapy with erenumab/fremanezumab for at least 1 year and discontinued it after achieving an adequate response (optimization). The evaluation of the response after retreatment included the following variables: DMM, MIDAS, and HIT-6 scales at the beginning of retreatment and 3 months later. The response was evaluated in different subgroups (episodic/chronic, erenumab/fremanezumab, and time until retreatment).
Results
48 patients were included. 70.8% (n = 34) required retreatment with mAb, with a median of 3.9 (2.9–6.4) months until reintroduction. Clinical response after retreatment was achieved in 67.6% (n = 23) of patients. No statistically significant differences were found in the analyzed subgroups.
Conclusion
Interruption of treatment with erenumab/fremanezumab for chronic/episodic migraine produces a clinical worsening of the disease requiring retreatment in most cases, approximately after 4 months. Two out of three patients respond positively after restarting monoclonal therapy. This response does not appear to be related to the type of migraine, the specific monoclonal antibody prescribed, or the time to retreatment.
期刊介绍：
Una gran revista para acceder a los mejores artículos originales y revisiones de la farmacoterapia actual. Además, es Órgano de expresión científica de la Sociedad Española de Farmacia Hospitalaria, y está indexada en Index Medicus/Medline, EMBASE/Excerpta Médica, Alert, Internacional Pharmaceutical Abstracts y SCOPUS.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
